As per MRFR analysis, the South Korea Anti-VEGF Market Size was estimated at 622.72 (USD Million) in 2023. The South Korea Anti-VEGF Market Industry is expected to grow from 649.5(USD Million) in 2024 to 1,054.8 (USD Million) by 2035. The South Korea Anti-VEGF Market CAGR (growth rate) is expected to be around 4.507% during the forecast period (2025 - 2035).
The South Korea Anti-VEGF market is undergoing significant trends as a result of the growing prevalence of eye diseases, particularly age-related macular degeneration and diabetic retinopathy.. The demand for anti-VEGF therapies is on the rise as a result of the increasing elderly population and the increasing number of individuals seeking treatment solutions. The government is actively promoting the development and approval of innovative treatment options, promoting the creation of rapid pathways that facilitate the timely access to novel therapies.
There is a substantial effort to advance drug delivery systems and personalized medicine, which is consistent with the global trend towards more effective and targeted treatments. Local biotech firms and pharmaceutical companies, particularly those that concentrate on the development of biosimilars to existing anti-VEGF medicines, have numerous opportunities. The regulatory environment in South Korea is conducive to innovation, and the potential for novel therapies to penetrate the market creates a significant opportunity for growth.
Academic institutions and enterprises are collaborating to promote research that has the potential to result in new therapies and discoveries, thereby improving the treatment options available in the market. The introduction of combination therapies, which combine anti-VEGF medications with other treatments to improve efficacy, has caused a shift in market dynamics in recent years.
This trend is indicative of the increasing recognition of the intricacy of ocular diseases and the necessity of comprehensive treatment strategies. Furthermore, healthcare organizations implement awareness campaigns to educate both practitioners and patients regarding the advantages of early diagnosis and treatment, which are essential for the effective management of ocular diseases in South Korea.
Source: Primary Research, Secondary Research, MRFR Database, and Analyst Review
The South Korea Anti-VEGF Market Industry is largely driven by the increasing prevalence of age-related macular degeneration (AMD). According to the Korean National Health Insurance Service, approximately 1.5 million South Koreans are diagnosed with AMD each year, a figure that has been progressively increasing. The growing elderly population, expected to constitute more than 20% of the South Korean population by 2025, underscores the urgent need for effective treatments.
As such, anti-VEGF therapies, which have shown efficacy in slowing the progression of AMD, are increasingly being adopted in clinical practice. This surge in demand for anti-VEGF treatments is bolstered by healthcare initiatives aimed at enhancing the healthcare system and increasing access to novel therapies. Renowned organizations such as the Korean Ophthalmological Society are actively promoting early diagnosis and treatment, further stimulating market growth.
Ongoing innovations in the anti-VEGF segment are substantially influencing the South Korea Anti-VEGF Market Industry. Recent launches of novel anti-VEGF agents, such as newer formulations with enhanced efficacy profiles, are becoming more common due to Research and Development initiatives by pharmaceutical companies.
For example, significant investments in Research and Development by companies such as Samsung Bioepis and Hanmi Pharmaceutical have resulted in new treatment options that cater to the unique needs of South Korean patients.The South Korean government has also been offering incentives to promote biopharmaceutical innovation, making it more feasible for companies to develop cutting-edge solutions.
The South Korean government has been formulating favorable healthcare policies aimed at improving patient access to anti-VEGF treatments. The Health Insurance Review and Assessment Service has recently revised coverage policies to include advanced anti-VEGF treatments, effectively reducing out-of-pocket expenses for patients. This type of government intervention is crucial given that accessibility directly impacts treatment choices among patients suffering from retinal diseases.
The National Health Insurance system now recognizes the importance of timely intervention. It is adapting its policies to ensure that affordable treatment options are available to a broader population, consequently driving growth within the South Korea Anti-VEGF Market Industry.
Enhanced awareness about ocular diseases and the importance of early detection has significantly contributed to the growth of the South Korea Anti-VEGF Market Industry. Various non-profit organizations and health care institutions in South Korea have initiated screening programs to bring attention to the risks associated with eye diseases such as diabetic retinopathy and macular degeneration.
The Korean Diabetes Association, for example, has reported that nearly 30% of patients with diabetes have some form of diabetic retinopathy, emphasizing the need for regular screenings.These initiatives aim to educate the public about the availability of treatment options, thereby driving the demand for anti-VEGF therapies as more patients seek timely intervention.
The South Korea Anti-VEGF Market presents a robust landscape driven by a variety of products aimed at treating conditions like age-related macular degeneration and diabetic retinopathy. Among these products, Eylea has gained substantial traction due to its efficacy in improving vision outcomes and extended dosing intervals, allowing for a more manageable treatment regimen for patients. Similarly, Lucentis has established its place in this market through its targeted approach and trust built over years of clinical usage, making it a preferred choice among ophthalmologists.
Additionally, Beovu, a newer entrant in the South Korea Anti-VEGF Market, is noted for its ability to offer competitive treatment options that address unmet needs in visual health. This product segment is characterized by ongoing research and development aimed at improving existing treatments and developing novel approaches to combat retinal diseases. Government initiatives and increasing healthcare expenditures in South Korea further support the growth of the Anti-VEGF product segment, fostering an environment of innovation and access to advanced therapies.
The market trends indicate a significant shift towards personalized medicine, with healthcare providers being actively engaged in tailoring treatments to individual patient needs. This engagement has led to a more dynamic market, encouraging pharmaceutical companies to invest in new solutions that align with the evolving landscape of medical practice. Moreover, the South Korea Anti-VEGF Market is influenced by an aging population and a rising prevalence of chronic eye diseases, creating a heightened demand for effective treatment options. Overall, the diverse product offerings within this segment cater to varying patient needs, driving competition and fostering advancement in treatment methodologies.
Source: Primary Research, Secondary Research, MRFR Database, and Analyst Review
The South Korea Anti-VEGF Market, particularly in the Disease segment, exhibits significant relevance, especially considering the increasing prevalence of retinal diseases within the population. The market is characterized by conditions such as Macular Edema, which often results from diabetes and is crucial for vision health, dominating the landscape due to its growing incidence. Diabetic Retinopathy also holds considerable significance as a leading cause of vision loss among working-age adults, emphasizing the need for effective anti-VEGF therapies.
Additionally, Retinal Vein Occlusion is a notable contributor to vision impairment, acting as a critical area of focus for healthcare providers. Age-Related Macular Degeneration represents a substantial challenge in the aging South Korean demographic, leading to a rising demand for advanced treatments.
Collectively, these conditions highlight the urgency for innovative interventions and healthcare strategies in the South Korea Anti-VEGF Market, driven by an aging population and lifestyle-related health concerns. The market dynamics reflect not just a response to the existing disease burden but also an opportunity for growth and advancement in ocular disease management.
The South Korea Anti-VEGF Market is characterized by a robust competitive landscape driven by the increasing prevalence of retinal diseases and the demand for innovative therapies. Anti-VEGF agents are critical in treating conditions such as age-related macular degeneration, diabetic retinopathy, and other ocular disorders. The market is witnessing significant investments in research and development, resulting in the introduction of novel therapies aimed at improving patient outcomes. A shift towards personalized medicine and the growing acceptance of biologics in treatment protocols are shaping market dynamics, amplifying the competition among key players.
Additionally, regulatory frameworks and healthcare expenditures in South Korea are conducive to the growth of this market, further intensifying competition among manufacturers and biopharmaceutical companies.In South Korea, Regeneron Pharmaceuticals has established a strong foothold in the anti-VEGF sector, particularly with its flagship product designed for ocular conditions. The company's extensive clinical trial data and established efficacy have solidified its reputation among healthcare professionals and patients alike. Regeneron's strength lies in its commitment to innovation and robust pipeline of anti-VEGF therapies, which are continually being refined and optimized based on feedback from clinical practice.
The company's strategic collaborations with local healthcare systems and participation in clinical research further enhance its market presence, allowing it to maintain a competitive edge while responding to the specific needs of the South Korean population. Regeneron's ongoing engagement with physicians and healthcare providers ensures that its products remain at the forefront of treatment options available in the anti-VEGF market.Zymeworks has also made notable strides within the South Korea Anti-VEGF Market, particularly with its proprietary biologic platforms that enable the development of differentiated therapies.
The company's focus on creating innovative treatments tailored to meet specific patient needs bodes well for its presence in this competitive landscape. Zymeworks has embarked on strategic partnerships and has been active in pursuing mergers and acquisitions to bolster its development capabilities and expand its market reach. Notable products under its development pipeline cater to ocular diseases, with emphasis on enhancing the efficacy and safety profile compared to existing therapies.
Zymeworks' strategy involves leveraging its novel biotherapeutic platforms to push the boundaries of conventional anti-VEGF treatment and build a significant presence in the South Korean market, where patient-centric solutions continue to drive demand for advanced therapies.
The South Korea Anti-VEGF Market has shown significant activity in recent months, particularly with advancements involving prominent companies such as Regeneron Pharmaceuticals and Novartis. In September 2023, Regeneron obtained regulatory approval for its Eylea injection, aimed at treating various retinal diseases, which marks a crucial development for the regional market. In addition, Zymeworks has been expanding its pipeline, focusing on anti-VEGF therapies, which has garnered attention among local investors. Companies like Amgen and Pfizer continue to enhance their portfolios in this space, with ongoing Research and Development efforts that align with South Korea's advanced healthcare infrastructure. Furthermore, recent months have seen considerable mergers and acquisitions, notably Santen Pharmaceutical's acquisition of a local firm to bolster its anti-VEGF portfolio in May 2023. The surge in market valuation has led to heightened competition, with Roche and AbbVie increasing their research capabilities and developing innovative strategies to capture a larger share. The consistent investment in healthcare technology by the South Korean government also supports the growth of this market, ensuring that it remains an evolving field with promising prospects for various stakeholders.
| Report Attribute/Metric Source: | Details |
| MARKET SIZE 2018 | 622.72(USD Million) |
| MARKET SIZE 2024 | 649.5(USD Million) |
| MARKET SIZE 2035 | 1054.8(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 4.507% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| MARKET FORECAST PERIOD | 2025 - 2035 |
| HISTORICAL DATA | 2019 - 2024 |
| MARKET FORECAST UNITS | USD Million |
| KEY COMPANIES PROFILED | Regeneron Pharmaceuticals, Zymeworks, Santen Pharmaceutical, Amgen, Novartis, Pfizer, GlaxoSmithKline, Roche, Sanofi, Apellis Pharmaceuticals, AbbVie, BristolMyers Squibb, Aldeyra Therapeutics, Eylea, Horizon Therapeutics |
| SEGMENTS COVERED | Product, Disease |
| KEY MARKET OPPORTUNITIES | Aging population increasing retinal disorders, Rising prevalence of diseases like AMD, Advancements in treatment delivery systems, Expansion of biosimilars market, Growing awareness and diagnosis rates |
| KEY MARKET DYNAMICS | increasing prevalence of retinal diseases, rising elderly population, advancements in drug formulations, government healthcare initiatives, competitive pricing strategies |
| COUNTRIES COVERED | South Korea |
Frequently Asked Questions (FAQ) :
The South Korea Anti-VEGF Market is expected to be valued at 649.5 million USD in 2024.
By 2035, the South Korea Anti-VEGF Market is projected to reach a value of 1054.8 million USD.
The expected CAGR for the South Korea Anti-VEGF Market from 2025 to 2035 is 4.507%.
The key products in the South Korea Anti-VEGF Market include Eylea, Lucentis, and Beovu.
The Eylea segment of the South Korea Anti-VEGF Market is valued at 250.0 million USD in 2024.
The Lucentis segment is forecasted to reach a value of 320.0 million USD by 2035.
In 2024, the Beovu segment is valued at 199.5 million USD.
Major players in the South Korea Anti-VEGF Market include Regeneron Pharmaceuticals, Novartis, and Roche.
Key growth drivers for the South Korea Anti-VEGF Market include increasing prevalence of eye disorders and advancements in treatment technology.
Emerging trends include the development of new therapies and expanded indications for existing anti-VEGF treatments.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Analyst Explore the profile of garvit vyas, one of our esteemed authors at market research future, and access their expert research contributions in the field of market research and industry analysis
Get in Touch
© 2025 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
